recombinant trivalent rotavirus subunit vaccine
/ MaxHealth Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
November 20, 2024
Safety and Immunogenicity Study of Recombinant Trivalent Rotavirus Subunit Vaccine in Healthy Infants and Toddlers
(clinicaltrials.gov)
- P2 | N=1512 | Active, not recruiting | Sponsor: MAXVAX Biotechnology Limited Liability Company | Trial completion date: Apr 2024 ➔ Dec 2024
Trial completion date • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Rotavirus Infections
May 23, 2023
Safety and Immunogenicity Study of Recombinant Trivalent Rotavirus Subunit Vaccine in Healthy Infants and Toddlers
(clinicaltrials.gov)
- P2 | N=1512 | Active, not recruiting | Sponsor: MAXVAX Biotechnology Limited Liability Company | Recruiting ➔ Active, not recruiting
Enrollment closed • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Rotavirus Infections
1 to 2
Of
2
Go to page
1